Drug Trial Radar · NCT07829549
Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Oct 10, 2026
Primary completion
Apr 2031
Study completion Aug 2031
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of RC148 plus platinum-based chemotherapy versus tislelizumab plus platinum-based chemotherapy in trial participants with previously untreated locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV), non-squamous non-small cell lung cancer without actionable genomic alterations.
Conditions
- Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
Interventions
RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin InjectionDrug
RC148, Pemetrexed Disodium, Carboplatin
Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin InjectionDrug
Tislelizumab, Pemetrexed Disodium, Carboplatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival assessed by BIRC per RECIST v1.1Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lin Wu
Hunan, Changsha, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.